MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-14-2026
Precipio Total Liabilities 2011-2026 | PRPO
Annual Total Liabilities Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.76 M | 4.9 M | 3.67 M | 5.14 M | 5.84 M | 6.55 M | 6.31 M | 15.5 M | 14.2 M | 20.6 M | 17.6 M | 23.5 M | 18.8 M | 18.5 M | 22.5 M | 22.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.5 M | 3.67 M | 13.3 M |
Quarterly Total Liabilities Precipio
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.64 M | 7.4 M | 6.53 M | 6.09 M | 4.9 M | 5.01 M | 5.2 M | 3.85 M | 3.67 M | 6.05 M | 5.38 M | 5.2 M | 5.14 M | 5.29 M | 5.41 M | 5.72 M | 5.84 M | 5.69 M | 6.28 M | 5.86 M | 6.55 M | 6.55 M | 6.55 M | 6.55 M | 6.31 M | 6.31 M | 6.31 M | 6.31 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 7.3 M | 7.3 M | 7.3 M | 20.6 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.5 M | 3.67 M | 12.1 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
366 M | $ 88.78 | -3.99 % | $ 4.15 B | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 5.1 | -11.46 % | $ 6.78 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 19.04 | -2.36 % | $ 586 M | USA |
 |
Castle Biosciences
CSTL
|
108 M | $ 21.38 | -1.02 % | $ 620 M | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 126.94 | -4.6 % | $ 15.9 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.79 | 2.29 % | $ 7.92 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Illumina
ILMN
|
2.7 B | $ 162.14 | -3.52 % | $ 25.1 B | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 22.29 | -3.59 % | $ 1.19 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 149.1 | -2.42 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 103.22 | 0.39 % | $ 6.97 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 10.96 | -3.09 % | $ 1.4 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 183.58 | -1.2 % | $ 9.1 B | USA |
 |
Natera
NTRA
|
686 M | $ 217.28 | -2.17 % | $ 29.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 454.91 | -0.82 % | $ 13.1 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.46 | -10.74 % | $ 438 M | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 157.67 | -1.93 % | $ 23.9 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.65 | -0.85 % | $ 431 M | USA |
 |
National Research Corporation
NRC
|
121 M | $ 19.5 | -1.27 % | $ 436 M | USA |
 |
Personalis
PSNL
|
73 M | $ 11.17 | -7.69 % | $ 997 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 26.21 | 0.81 % | $ 24.9 B |  Niderland |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.78 | -3.28 % | $ 283 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.21 | 3.03 % | $ 5.08 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 264.33 | 1.23 % | $ 22 B | USA |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 70.6 | -4.51 % | $ 4.22 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 474.92 | -1.49 % | $ 179 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.72 | 4.53 % | $ 259 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 8.96 | -1.81 % | $ 1.94 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 200.0 | 1.96 % | $ 22.2 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |